Endogenous androgens and sex hormone-binding globulin in women and risk of metabolic syndrome and type 2 diabetes

Benjamin Fenske, Hanna Kische, Stefan Gross, Henri Wallaschofski, Henry Völzke, Marcus Dörr, Matthias Nauck, Brian G. Keevil, Georg Brabant, Robin Haring

Research output: Contribution to journalArticleResearchpeer-review

41 Citations (Scopus)


Context and Objectives: The association of endogenous androgens and sex hormone-binding globulin (SHBG) with metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM) mostly 23562 refers to small and selected study samples with immunoassay-based measurements. Thus, we investigated the association of hormone levels with MetS and T2DM in women from a large population-based sample. Design, Setting, and Participants: A total of 2077 women from the Study of Health in Pomerania were assessed at baseline (N = 3160, 1997-2001) and 5-year follow-up (N = 1711, 2002-2006). Main Outcomes and Measures: We investigated associations of total testosterone (T) and androstenedione measured by liquid chromatography-tandem mass spectrometry, SHBG by immunoassay, and free T and free androgen index with MetS and T2DM. Results: Baseline prevalence of MetS and T2DM was 23.1% (N = 365) and 9.5% (N = 196), with an incidence of 17.7 and 7.0 per 1.000 person-years, respectively. Cross-sectional analyses yielded inverse associations of SHBG with MetS (relative risk [RR], 0.67; 95% confidence interval [CI], 0.60-0.74) and T2DM (RR, 0.61; 95% CI, 0.50-0.74) after multivariable adjustment. In longitudinal analyses, only age-adjusted models showed an inverse association of baseline SHBG with incident MetS (RR, 0.61; 95% CI, 0.51-0.73) and T2DM (RR, 0.58; 95% CI, 0.43-0.78). Multivariable-adjusted models stratified by menopausal status revealed an inverse association betweenSHBGand incident MetS risk in postmenopausal women (RR, 0.65; 95% CI, 0.51-0.81). Conclusions: This longitudinal population-based study revealed independent inverse associations of SHBG with MetS and T2DM, suggesting low SHBG as a potential risk marker for cardiometabolic morbidity, especiallyamongpostmenopausal women.

Original languageEnglish
Pages (from-to)4595-4603
Number of pages9
JournalThe Journal of Clinical Endocrinology and Metabolism
Issue number12
Publication statusPublished - Dec 2015
Externally publishedYes

Cite this